Hyperfine Inc (HYPR) Peer Comparison
$0.75
$-0.03
(-3.24%)
As on 16-Oct-2026 16:00EDT
Market cap
$99 Mln
Revenue (TTM)
$17 Mln
P/E Ratio
--
P/B Ratio
2.3
Div. Yield
0 %
Edit
| Hyperfine Inc (HYPR) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
99 | 4,952 | 3,312 | 609 | 462 |
Revenue ($ Mln) |
17 | 440 | 2,883 | -- | 330 |
Net Profit ($ Mln) |
-34.85 | -1,435.01 | -118.30 | -134.20 | 100.20 |
Net Margin (%) |
-210.75 | -325.91 | -4.10 | -- | 30.33 |
RoE (%) |
-89.64 | -- | -- | -40.17 | 30.44 |
Price to Earnings |
-- | -- | -- | -- | 4.87 |
Price-To-Book |
2.32 | -- | 1.35 | -- | 1.27 |
Income Statement ($ Mln)
| Hyperfine Inc (HYPR) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
13.56 | 319.02 | 2,631.80 | -- | 335.44 |
|
Cost of Revenue
|
6.81 | 281.12 | 1,584.40 | -- | 46.04 |
|
Gross Profit
|
6.75 | 37.90 | 1,047.40 | -- | 289.40 |
|
Operating Expenses
|
43.84 | 262.45 | 899.40 | 0.17 | 146.67 |
|
Operating Profit (EBIT)
|
-37.09 | -224.55 | 148.00 | -0.17 | 142.73 |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
-35.57 | -288.03 | -159.30 | 0.38 | 142.73 |
|
Provision for Tax
|
-- | 0.58 | 16.20 | -- | 35.94 |
|
Profit after Tax (Net Income)
|
-35.57 | -288.62 | -198.30 | 0.38 | 106.84 |
|
Minority Interest
|
-- | -- | 143.50 | -- | 0.00 |
|
Consolidated Profit
|
-- | -- | -- | -- | -- |
Liabilities ($ Mln)
| Hyperfine Inc (HYPR) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
41.01 | -962.74 | -1,276.40 | 399.79 | 317.57 |
|
Minority Interest
|
-- | -- | 143.50 | -- | 0.00 |
|
Non-Current Liabilities
|
2.53 | 2,528.98 | 3,507.00 | 15.99 | 160.23 |
|
Current Liabilities
|
11.73 | 781.40 | 2,868.70 | 0.13 | 594.94 |
|
Total Liabilities
|
55.26 | 2,347.64 | 5,244.20 | 415.91 | 1,072.73 |
Assets ($ Mln)
| Hyperfine Inc (HYPR) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
4.35 | 1,452.11 | 3,924.70 | 414.85 | 349.32 |
|
Current Assets
|
50.91 | 895.54 | 1,319.50 | 1.06 | 723.41 |
|
Total Assets
|
55.26 | 2,347.64 | 5,244.20 | 415.91 | 1,072.73 |
|
Total Debt*
|
0.31 | 1,060.33 | 3,975.30 | -- | 152.49 |
|
Net Current Assets
|
39.18 | 114.14 | -1,558.20 | 0.93 | -- |
Cashflow ($ Mln)
| Hyperfine Inc (HYPR) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-27.95 | 278.25 | 24.80 | -0.63 | 71.03 |
|
Cash Flow from Investing Activities
|
-1.19 | -740.75 | -12.20 | -414.00 | 0.62 |
|
Cash from Financing Activities
|
27.50 | -63.10 | 114.30 | 415.37 | -1.08 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Hyperfine Inc (HYPR) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-78.51 | -120.97 | -7.47 | -- | 24.90 |
|
ROE (%)
|
-79.01 | 32.38 | 17.08 | -- | 38.62 |
|
ROA (%)
|
-62.32 | -14.63 | -3.83 | -- | 9.34 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-262.29 | -90.47 | -7.53 | -- | 31.85 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Hyperfine Inc (HYPR) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
0.05 | -0.38 | -0.18 | -- | 0.13 |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
12.64 | 78.05 | -54.32 | -- | 41.10 |
|
EPS Growth (%)
|
0.32 | 0.80 | -0.54 | -- | 0.40 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Hyperfine Inc (HYPR) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-2.59 | -19.80 | -13.35 | -- | 5.90 |
|
Price / Book Value
|
2.25 | -5.94 | -2.07 | -- | 1.99 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-1.67 | -31.10 | 5.65 | -- | 2.94 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Hyperfine Inc (HYPR) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.01 | -1.10 | -3.11 | -- | 0.48 |
|
Short term debt to equity ratio
|
0.01 | -0.03 | -1.08 | -- | 0.00 |
|
Current Ratio
|
4.34 | 1.15 | 0.46 | 8.13 | 1.22 |
|
Quick Ratio
|
3.73 | -- | -- | -- | -- |
|
Interest Coverage
|
-- | -87.90 | 0.39 | -- | 14.20 |
Operating Efficiency Ratios
| Hyperfine Inc (HYPR) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
48.09 | 105.69 | 29.34 | -- | 61.95 |
|
Asset Turnover
|
0.24 | 0.16 | 0.51 | -- | 0.29 |
|
Receivable days
|
199.64 | 193.60 | 125.70 | -- | 281.90 |
|
Inventory Days
|
346.53 | -5.77 | -5.88 | -- | -1,881.69 |
|
Payable days
|
151.73 | 94.44 | 58.42 | -- | 1,383.94 |
|
Cash Conversion Cycle
|
394.44 | -84.42 | 68.68 | -- | -1,771.50 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
